Correction: Formulation and Optimization of Repaglinide Nanoparticles Using Microfluidics for Enhanced Bioavailability and Management of Diabetes (Biomedicines, (2023), 11, 4, (1064), 10.3390/biomedicines11041064)

In the original publication, there was an inadvertent labeling mistake in Figure 11A as published [1]. Figure 11A was mistakenly mislabeled as corresponding to the control group. In fact, it is a second image from the Rp-Nc 1 mg-treated group. This image was captured from the same sample as that shown in Figure 11D. As a result, there is a slight overlap in one corner of Figure 11A,D, since both represent the same treatment group. Because we were capturing images from different parts of the organs, unintentional mislabeling occurred. The corrected version of Figure 11 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.